Published in Am J Hematol on January 01, 1986
Systematic reviews and meta-analyses on treatment of asthma: critical evaluation. BMJ (2000) 5.43
The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA (1995) 5.05
The Internet and evidence-based decision-making: a needed synergy for efficient knowledge management in health care. CMAJ (2000) 3.46
A guide to interpreting discordant systematic reviews. CMAJ (1997) 2.29
Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summ) (2005) 1.63
Systemic adjuvant therapy for node-negative breast cancer. CMAJ (1989) 1.42
Science, language, intuition, and the many meanings of quality of life. J Clin Oncol (1999) 1.42
Scientific evidence and expert opinion in ACP Journal Club: commentary on commentaries. ACP J Club (1994) 1.40
Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation. BMJ Qual Saf (2011) 1.39
Pharmacological treatment of dementia. Evid Rep Technol Assess (Summ) (2004) 1.38
Internet use among physicians, nurses, and their patients. JAMA (2001) 1.32
The contribution of cytochemistry and immunophenotyping to the reproducibility of the FAB classification in acute leukemia. Blood (1986) 1.26
A controlled "before-after" study: impact of a clinical guidelines programme and regional cancer network organization on medical practice. Br J Cancer (2002) 1.24
When is a prognostic factor useful? A guide for the perplexed. J Clin Oncol (1991) 1.20
Development and aftercare of clinical guidelines: the balance between rigor and pragmatism. JAMA (2001) 1.16
The treatment of attention-deficit hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic reviews and metaanalyses. Can J Psychiatry (1999) 1.13
Funding new cancer drugs in Ontario: closing the loop in the practice guidelines development cycle. J Clin Oncol (2001) 0.98
Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure. Evid Rep Technol Assess (Full Rep) (2006) 0.96
Searching the medical literature for the best evidence to solve clinical questions. Ann Oncol (1998) 0.92
Resistance to photodynamic therapy in radiation induced fibrosarcoma-1 and Chinese hamster ovary-multi-drug resistant. Cells in vitro. Photochem Photobiol (1991) 0.84
Health care professionals' familiarity with non-pharmacological strategies for managing cancer pain. Psychooncology (1999) 0.83
Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials. Int J Radiat Oncol Biol Phys (2001) 0.83
The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. Br J Cancer (1992) 0.82
Hepatic hyperthermia by total isolation and regional perfusion in vivo. J Surg Res (1979) 0.81
Trends in hormonal management of prostate cancer: a population-based study in Ontario. Med Care (2001) 0.79
Comparison of leucovorin protection from variety of antifolates in human lymphoid cell lines. Cancer Chemother Pharmacol (1985) 0.79
Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol (1995) 0.79
A complement independent erythropoietic inhibitor acting on the progenitor cell in refractory anemia. Am J Med (1976) 0.79
Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer. J Clin Oncol (1983) 0.78
Classifying acute leukemia by immunophenotyping: a combined FAB-immunologic classification of AML. Blood (1986) 0.78
Criteria for weaning from mechanical ventilation. Evid Rep Technol Assess (Summ) (2000) 0.78
Enhancement of the therapeutic effectiveness of methotrexate and protection of normal proliferating tissues with purines and pyrimidines. Chem Biol Interact (1977) 0.78
Chemoprevention for lung cancer--evidence for a high degree of compliance. Cancer Detect Prev (1990) 0.77
Etretinate blood levels in monitoring of compliance and contamination in a chemoprevention trial. J Natl Cancer Inst (1989) 0.77
Introduction to a series of systematic reviews of weaning from mechanical ventilation. Chest (2001) 0.77
Bench-to-bedside research and the human tumor stem-cell assay--bridging the credibility gap. J Clin Oncol (1986) 0.76
Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays. Leuk Lymphoma (1993) 0.76
Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma. Acta Oncol (1999) 0.76
Relation between platinum-DNA adducts and complete remission in adult acute nonlymphocytic leukemia. Leuk Res (1994) 0.75
The BC Cancer Agency Compassionate Access Program: outcome analysis of patients with esophagogastric cancer. Curr Oncol (2009) 0.75
Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside. Br J Haematol (1984) 0.75
Survival results from a phase III study of simultaneous versus 1-hour sequential methotrexate-5-fluorouracil chemotherapy in head and neck cancer. Head Neck Surg (1986) 0.75
Should-alpha-interferon be included as standard treatment in multiple myeloma? Eur J Cancer (1998) 0.75
Studies with a 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (DDMP)-resistant L1210 leukemia cell line without cross-resistance to methotrexate. Biochem Pharmacol (1980) 0.75
The intracellular mechanism of action of metoprine (DDMP). Eur J Cancer (1980) 0.75
Inhibition of DNA synthesis by cytosine arabinoside: relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease. Eur J Cancer Clin Oncol (1984) 0.75
Clinical evidence of a cumulative effect of high-dose cytarabine on the cerebellum in patients with acute leukemia: a leukemia intergroup report. Cancer Treat Rep (1985) 0.75
Comparison of thymidine and folinic acid protection from methotrexate toxicity in human lymphoid cell lines. Cancer Treat Rep (1982) 0.75
Development of clinical practice guidelines: surgical perspective. World J Surg (1999) 0.75
Optimal conditions for immunohistochemical determination of the in vitro DNA synthesis labelling index with bromodeoxyuridine in head and neck cancer. Cell Prolif (1991) 0.75
[Tools for the practice of evidence based medicine (I). Update in evidence based information resources for clinical practice]. Med Clin (Barc) (2000) 0.75
Modification of in vivo methotrexate antitumor effect in L1210 leukemia by induced impairment of purine salvage. Biochem Pharmacol (1981) 0.75
Combination antifol therapy: observations on the development of resistant L1210 leukemic cells in vivo. Cancer Treat Rep (1980) 0.75
Perceptural-motor and academic relationships for disadvantaged children classified as learning disabled and normal. Am Correct Ther J (1974) 0.75
Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: relationship to response to remission induction therapy. Eur J Cancer Clin Oncol (1985) 0.75
Differential calcium leucovorin protection of human lymphoid cell lines from methotrexate. Cancer Chemother Pharmacol (1985) 0.75
Dogs bites. JAMA (1985) 0.75
A pilot study of carboplatin augmentation therapy for patients with poor risk acute non-lymphocytic leukemia. Leuk Res (1992) 0.75
Acute puerperal inversion of the uterus. Med J Malaysia (1978) 0.75
Choriocarcinoma--an unusual case. Med J Malaysia (1978) 0.75
Implications of using a prognostic index to select therapy for patients with aggressive histology lymphoma. Can J Oncol (1995) 0.75
Clinical application of the concept of methotrexate plus 5-FU sequence-dependent "synergy": how good is the evidence? Cancer Treat Rep (1984) 0.75